The following information was derived from data with oral aprepitant
and one study conducted with fosaprepitant and oral midazolam.
was generally well tolerated when administered as 375 mg once daily for up to 42 days to patients in non-CINV studies.
New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant
when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods
2] Metoclopramide PONV receptor Domperidone PINV (metoclopramide) Prochlorperazine 5-HT3 Ondansetron CINV (acute) receptor Tropisetron PONV antagonists Substance P Aprepitant
CINV (delayed) NK-1 receptor PONV antagonists Histamine [H.
Daniele Santini and coworkers at the Universita "Campus Bio-Medico" di Roma presented a study of 22 patients with severe pruritus treated with aprepitant
using a regimen of 125 mg on day 1 and 80 mg on days 3 and 5.
Fosaprepitant 115 mg IV on d 1 only, and then aprepitant
80 mg [d.
The present study was performed to evaluate the potential effect of aprepitant
40 mg on CYP2C9 activity and to evaluate the safety and tolerability of coadministration of aprepitant
40 mg and tolbutamide 500 mg.
To prevent delayed emesis in patients receiving cisplatin and other high emetic risk agents, dexamethasone and aprepitant
is recommended on day 2 and 3 as well.
3]RA, corticosteroids, and/or aprepitant
for prevention of acute emesis with MEC and HEC (10, 11).
Raltegravir supply framework (DOE) and aprepitant
Development of aprepitant
, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Patients were randomly assigned (at a 3:1 ratio) to receive NEPA plus dexamethasone or aprepitant
plus oral palonosetron and dexamethasone.
One of the new antiemetic drugs, aprepitant
(Emend), is an antagonist of the NK-1 receptor.
The concomitant use of fentanyl transdermal system with all cytochrome P450 3A4 inhibitors (such as ritonavir, ketoconazole, itraconazole, troleandomycin, clarithromycin, nelfinavir, nefazodone, amiodarone, amprenavir, aprepitant
, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, and verapamil) may result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.
New data presented at the 14th World Conference on Lung Cancer in Amsterdam, The Netherlands, show the efficacy of the 2nd generation 5-HT<sub>3receptor antagonistalone and in combination with aprepitant